Annexon reports Q3 2022 net loss of $35.1M, cash $269.5M; pipeline updates in Jan 2023

Annexon, Inc.

2022-Q3 EPS reported -$2.21

Net loss of $35.1M ($0.51 per share) vs $35.6M ($0.93 per share) in Q3 2021.
Cash & equivalents $269.5M as of Sep 30, 2022; runway into H2 2025.
R&D expenses $27.9M and G&A $8.2M, both essentially flat year-over-year.
Portfolio updates across autoimmune, neurodegeneration and ophthalmology franchises planned for Jan 2023.
ANX005 HD Phase 2 data shows reduced neuroinflammation; regulator engagement by year-end; ANX007 GA Phase 2 data expected H1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Annexon, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss was $35.1 million or $0.51 per share for the quarter ended September 30, 2022, EPS $0.51 per share.

Period: the third quarter ended September 30, 2022
Net income: Net loss was $35.1 million or $0.51 per share for the quarter ended September 30, 2022
EPS: $0.51 per share
Result: reported results

Exact text from the filing

Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today reported third quarter 2022 financial results.

View on SEC.gov

Browse all earnings releases →

Annexon, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-021512

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.